About Us
Zydus Lifesciences is a global, innovation-driven life sciences company committed to empowering people to live healthier and more fulfilled lives. With a presence across India, the United States, Europe, Latin America and other emerging markets, the organisation continues to expand access and affordability through patient-centric, science-led healthcare solutions.
Zydus draws strength from a rich legacy that began in 1952, when Mr. Ramanbhai B. Patel, a first-generation entrepreneur and a respected pioneer of the Indian pharmaceutical industry, laid its foundation. In 1995, the group was restructured, leading to the formation of Cadila Healthcare under the aegis of the Zydus Group, a milestone that shaped its modern identity.
Research lies at the core of our work. From advancing New Chemical Entities to strengthening capabilities in biologics and vaccines, Zydus is focused on addressing unmet healthcare needs through pathbreaking discoveries. This research-driven approach is complemented by a patient-centric philosophy that ensures innovation translates into meaningful health outcomes.
Seven Decades of
Legacy, Trust and
Innovation
0
Legacy Years
Rs. 0
Employees Globally
0
R&D Scientists
0
Manufacturing Facilities
0
R&D Centres
0
Generic company in the US in terms of prescriptions
Zydus’ journey of many firsts
Lipaglyn® (Saroglitazar)
India’s first indigenously discovered New Chemical Entity and the world’s first approved Glitazar – a pathbreaking therapy for diabetic dyslipidaemia.
Adalimumab (Exemptia®)
World’s first biosimilar of Adalimumab in India — expanding access to biologics for autoimmune diseases
TwinRab™
World’s first novel biological entity for rabies prophylaxis – an innovative monoclonal antibody cocktail developed for rabies post-exposure prophylaxis.
Ujvira (Trastuzumab Emtansine biosimilar)
World’s first biosimilar Antibody Drug Conjugate (ADC) – a breakthrough therapy for the treatment of early and advanced HER2-positive breast cancer.
Oxemia™ (Desidustat)
India’s first oral HIF-PH inhibitor for anaemia in chronic kidney disease – a novel therapy offering an alternative to injectable treatment options.
VaxiFlu4
India’s first trivalent inactivated influenza vaccine – designed to provide broader protection against influenza virus strains.
Tishtha™ (Nivolumab biosimilar)
World’s first biosimilar of Nivolumab – expanding access to advanced immuno-oncology treatment for multiple cancers.
Usnoflast
First-in-class novel oral NLRP3 inhibitor from Zydus – currently under clinical development for inflammatory and neurodegenerative diseases such as ALS, Parkinson’s disease, CAPS and ulcerative colitis.
Our Mission
Be a global life-sciences company transforming lives through pathbreaking discoveries.
Our Vision
To unlock new possibilities in life-sciences through quality healthcare solutions that impact lives.
Our Purpose
Empower people with the freedom to live healthier and more fulfilled lives.
Core Behaviours
Zydus First
Putting organisation before self
Excellence in execution
Being action-oriented
Adaptability to change
Keeping pace with change
Innovation
Being innovative in all that we do
Team & Collaboration
We not ‘I’
Respect, Trust & Integrity
Doing the right things, in the right way at the right time